- Home
- RNAZ vs SNOA Comparison
RNAZ vs SNOA Comparison
Compare RNAZ & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- SNOA
- Stock Information
- Founded
- RNAZ 2016
- SNOA 1999
- Country
- RNAZ United States
- SNOA United States
- Employees
- RNAZ N/A
- SNOA N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- SNOA Health Care
- Exchange
- RNAZ Nasdaq
- SNOA Nasdaq
- Market Cap
- RNAZ 6.1M
- SNOA 6.4M
- IPO Year
- RNAZ 2021
- SNOA 2007
- Fundamental
- Price
- RNAZ $9.11
- SNOA $3.68
- Analyst Decision
- RNAZ Strong Buy
- SNOA
- Analyst Count
- RNAZ 1
- SNOA 0
- Target Price
- RNAZ $280.00
- SNOA N/A
- AVG Volume (30 Days)
- RNAZ 26.1K
- SNOA 79.8K
- Earning Date
- RNAZ 08-13-2025
- SNOA 08-07-2025
- Dividend Yield
- RNAZ N/A
- SNOA N/A
- EPS Growth
- RNAZ N/A
- SNOA N/A
- EPS
- RNAZ N/A
- SNOA N/A
- Revenue
- RNAZ N/A
- SNOA $14,288,000.00
- Revenue This Year
- RNAZ N/A
- SNOA $38.54
- Revenue Next Year
- RNAZ N/A
- SNOA N/A
- P/E Ratio
- RNAZ N/A
- SNOA N/A
- Revenue Growth
- RNAZ N/A
- SNOA 12.20
- 52 Week Low
- RNAZ $6.15
- SNOA $1.75
- 52 Week High
- RNAZ $905.52
- SNOA $9.00
- Technical
- Relative Strength Index (RSI)
- RNAZ 55.86
- SNOA 63.82
- Support Level
- RNAZ $8.04
- SNOA $2.97
- Resistance Level
- RNAZ $9.70
- SNOA $4.15
- Average True Range (ATR)
- RNAZ 0.67
- SNOA 0.24
- MACD
- RNAZ 0.27
- SNOA 0.10
- Stochastic Oscillator
- RNAZ 75.08
- SNOA 64.93
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.